medRxiv preprint doi: https://doi.org/10.1101/2024.11.06.24316481; this version posted November 7, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

Evaluating metabolome-wide causal effects on risk for psychiatric and neurodegenerative disorders

- Lachlan Gilchrist^{1,2}, Julian Mutz¹, Pirro Hysi^{3,4,5}, Cristina Legido-Quigley^{6,7}, Sulev Koks^{8,2}, Cathryn M. Lewis^{1,9,*} and Petroula Proitsi^{10,11,*}
- ¹ Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology &
- Neuroscience, King's College London, London, United Kingdom
- ² Perron Institute for Neurological and Translational Science, Perth, Australia
- ³ Department of Ophthalmology, King's College London, London, UK
- ⁴ Department of Twins Research and Genetic Epidemiology, King's College London, London, UK
- ⁵ Sørlandet Sykehus Arendal, Arendal, Norway
- ⁶ Systems Medicine, Institute of Pharmaceutical Science, Life Science & Medicine, King's College
- London, London, UK
- ⁷ Steno Diabetes Center Copenhagen, Copenhagen, Denmark
- ⁸ Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Perth, Australia
- ⁹ Department of Medical and Molecular Genetics, King's College London, London, United Kingdom
- ¹⁰ Centre for Preventive Neurology, Wolfson Institute of Population Health, Queen Mary's University of
- London
- ¹¹ Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology, and
- Neuroscience, King's College London, London, United Kingdom

23 * equally contributing authors/co-corresponding authors: Dr. Petroula Proitsi

- (p.proitsi@qmul.ac.uk) and Prof. Cathryn Lewis (cathryn.lewis@kcl.ac.uk)

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2024.11.06.24316481; this version posted November 7, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

41

Abstract

42 and biological overlap between Evidence indicates phenotypic psychiatric and 43 neurodegenerative disorders. Further identification of underlying mutual and unique biological 44 mechanisms may yield novel multi-disorder and disorder-specific therapeutic targets. The 45 metabolome represents an important domain for target identification as metabolites play 46 critical roles in modulating a diverse range of biological processes. Here, we used Mendelian 47 randomisation (MR) to test the causal effects of ~1000 plasma metabolites and ~300 metabolite ratios on anxiety, bipolar disorder, depression, schizophrenia, amyotrophic lateral 48 49 sclerosis, Alzheimer's disease, Parkinson's disease and multiple sclerosis. In total, 85 causal 50 effects involving 77 unique metabolites passed FDR correction and robust sensitivity analyses 51 (IVW-MR OR range: 0.73-1.48; $p_{FDR} < 0.05$). No evidence of reverse causality was identified. 52 Multivariate analyses implicated sphingolipid metabolism in psychiatric disorder risk and carnitine derivatives in risk for amyotrophic lateral sclerosis and multiple sclerosis. However, 53 polygenic risk scores for prioritised metabolites showed limited prediction in the UK Biobank. 54 55 Downstream colocalisation in regions containing influential variants identified greater than 56 suggestive evidence (PP.H₄ \ge 0.6) for a shared causal variant for 29 metabolite/psychiatric 57 disorder trait-pairs on chromosome 11 at the FADS gene cluster. Most of these metabolites 58 were lipids containing linoleic or arachidonic acid. Additional colocalisation was identified 59 between the ratio of histidine-to-glutamine, glutamine, Alzheimer's disease and SPRYD4 gene expression on chromosome 12. Although no single metabolite had a causal effect on a 60 psychiatric and a neurodegenerative disease, results suggest a broad effect of lipids across 61 62 brain disorders. Metabolites identified here may help inform future targeted interventions.

medRxiv preprint doi: https://doi.org/10.1101/2024.11.06.24316481; this version posted November 7, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

63 1. Introduction

Psychiatric disorders show substantial co-morbidity¹ 64 and shared genetic architecture². Additionally, are common both 65 they prior to and within neurodegenerative diseases³⁻⁷ – themselves genetically related^{8,9} – and are indicated 66 as risk factors for their later onset^{10–12}. Genomic analyses suggest that psychiatric and 67 neurodegenerative risk are partially underpinned by shared risk loci and causal brain 68 transcripts and proteins^{13–17}. By further investigating shared biological risk 69 70 mechanisms, novel interventions may be identified with effectiveness for specific or 71 multiple disorders.

Metabolomics – the study of small molecules linked to metabolism – is a promising tool for such investigation as it represents the stage of the omics cascade closest to the phenotype¹⁸. Importantly, metabolites are strong drug target candidates as many are obtained dietarily and modulate diverse biological processes including gene expression, RNA metabolism and protein activity^{19–21}. Obtaining samples is minimally invasive as thousands of metabolites can be detected in plasma, serum or urine²².

79 Similar metabolite groups, such as ceramides, are indicated to play a role in both psychiatric and neurodegenerative disorders^{23–27}. However, observational 80 studies may be confounded by reverse causation²⁸. Importantly for psychiatric and 81 neurodegenerative disorders, the metabolome can be perturbed by disease 82 83 pathology and/or pharmaceutical interventions²⁹⁻³³. As such, following onset and 84 treatment discerning the direction of effect and identifying causal metabolite targets 85 is challenging. These limitations can be addressed using Mendelian randomisation 86 (MR), a statistical framework that leverages genetic variants as instrumental variables (IVs) to proxy an exposure and infer its causal effect on an outcome of interest³⁴. As 87 risk alleles are randomly assorted and fixed from conception, MR is less vulnerable 88 89 to reverse causality than classical epidemiological approaches^{28,35}. Beneficially, this 90 approach can be performed using summary statistics from large genome-wide 91 association studies (GWAS) (two-sample MR (2SMR)), allowing researchers to perform increasingly powerful analyses³⁶. This approach applied to the metabolome 92 93 has already identified several causal risk metabolites for Alzheimer's disease, bipolar disorder, major depressive disorder, and multiple sclerosis³⁷⁻⁴¹. 94

However, no study has yet been conducted to identify shared and unique
metabolomic risk factors across the psychiatric and neurogenerative disorder
spectrum. In this study, we assess the causal effect of ~1000 unique plasma
metabolites and ~300 metabolite ratios on four psychiatric disorders (anxiety, bipolar
disorder, depression and schizophrenia) and four neurodegenerative diseases
(amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease

medRxiv preprint doi: https://doi.org/10.1101/2024.11.06.24316481; this version posted November 7, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

101 (PD) and multiple sclerosis (MS)). We further prioritise key metabolites using

Bayesian model averaging, identify regions of shared causal variants with statistical
 colocalisation – integrating expression quantitative trait loci (eQTLs) – and assess the

104 predictive performance of polygenic scores for risk metabolites on incident diseases

105 in the UK Biobank (UKB).

106 2. Methods

107 An overview of the analyses is shown in Figure 1.



108

- Figure 1: Analysis flowchart. In the Mendelian randomisation section, the three key assumptions are
 illustrated and can be described as: (1) Instruments must be robustly associated with the exposure –
 usually defined as genome-wide statistical significance of the variants; (2) Instruments are not
- 112 associated with a confounder and (3) Instruments are not associated with the outcome via pathways
- 113 other than through the exposure, for example through horizontal pleiotropy. These assumptions are
- 114 *known as the (1) relevance, (2) independence and (3) exclusion restriction assumption, respectively.*
- ANX = anxiety; ALS = amyotrophic lateral sclerosis; AD = Alzheimer's disase; BP = bipolar disorder;
- 116 *DEP = depression; MS = multiple sclerosis; PD = Parkinson's disease; SCZ = schizophrenia*
- 117

118 2.1 GWAS summary statistics

119 2.1.1 Neuropsychiatric disorders

An overview of the GWAS summary statistics is shown in Table 1. These consisted of 120 121 individuals of European ancestry only. For each disorder, we performed inverse 122 variance weighted (IVW) genome-wide meta-analysis across samples^{9,42-51} using METAL⁵² to maximise sample size and statistical power. Details on each sample can 123 been seen in the original papers. For AD, we used summary statistics that did not 124 contain family history-based proxy phenotyping from the UK Biobank given its noted 125 influence on the effect direction of downstream analyses⁵³. The APOE region 126 (chr19:45,020,859-45,844,508 (GRCh37)) was excluded from the AD GWAS due to 127 known pleiotropic effects on relevant non-AD diseases such as heart disease and 128 hypercholesterolaemia⁵⁴. It was not meta-analysed with FinnGen freeze 9 as with the 129 others as the sample already contained samples from a previous FinnGen freeze. 130 Genetic correlations between these disorders - calculated using Linkage 131 Disequilibrium Score Regression (LDSC)⁵⁵ in GenomicSEM⁵⁶ v.0.0.5 – are described 132 and plotted in Supplementary Material 1 and 2, respectively. Full output tables are 133 in Supplementary Tables 1 and 2. Effective sample sizes were calculated as per 134 Grotzinger et al.⁵⁷, providing comparable sample size estimates representing 135 136 equivalently powered GWAS with a 1:1 case/control ratio.

Category	Phenotype	GWAS sample	N Cases	N Controls	Total cases	Total controls	N _{eff}
Psychiatric	Anxiety	Purves et al.	25,453	58,113	70,228	354,864	226,035
		Meier et al. (iPSYCHE)	4,584	19.225			
		Finngen Freeze 9 (KRA_PSY_ANXIETY)	40,191	277,526			
	Bipolar disorder	Mullins et al.	41,917	371,549	48,923	651,818	129,398
		Finngen freeze 9 (F5_BIPO)	7,006	329,192			
	Depression	Million Veterans Project	83,810	166,405	298,038	824,848	825,105
		Psychiatric Genomics Consortium/ UK Biobank (Howard et al.)	170,756	329,443			
		Finngen freeze 9 (F5_DEPRESSIO)	43,280	329,192			
	Schizophrenia	Trubetskoy et al.	53,386	77,258	66,447	354,784	176,178
		Finngen freeze 9 (KRA_PSY_SCHIZODEL)	13,061	277,526			
Neurodegenerative	Alzheimer's disease	Wightman et al. (excl. UKB)	39,918	358,140	39,918	358,140	89,308
	Amyotrophic lateral sclerosis	van Rheenen et al.	27,205	110,881	27,686	281,548	115,084
		Finngen freeze 9 (G6_ALS)	483	170,667			
	Multiple Sclerosis	International Multiple Sclerosis Consortium	47,429	68,374	49,611	442,361	120,692
		Finngen freeze 9	2,182	373,987			
	Parkinson's disease	Nalls et al.	33,674	449,056	37,441	822,098	120,692
		Finngen freeze 9	4.235	373.042			

Table 1: Previously conducted genome-wide association study summary statistics for psychiatric and
neurodegenerative disorders used in this study.

140

141 2.1.2 Plasma metabolites

We obtained metabolite summary statistics from two studies conducted in non-142 143 overlapping samples: (1) 1,091 individual metabolites and 309 metabolite ratios 144 measured in 8,299 unrelated individuals from the Canadian Longitudinal Study of Aging (CLSA)⁵⁸ and (2) 722 individual metabolites measured in 8,809 individuals in 145 the NIHR UK Bioresource cohort⁵⁹. In both studies, metabolites were detected and 146 quantified in plasma by Metabolon Inc. using ultra-high performance liquid 147 148 chromatography-tandem mass spectroscopy. Unidentified metabolites were excluded from analyses. We performed genome-wide meta-analysis as above for 431 149 150 metabolites when the same metabolite was available in both samples for a metaanalysed sample size of 17,038. 151

152

153 2.1.3 GWAS standardisation

Prior to meta-analysis, summary statistics were standardised with MungeSumstats⁶⁰ 154 144 155 version in R (v.4.2.1)using dbsnp and the BSgenome.Hsapiens.1000genomes.hs37d5 reference genome available through 156 Bioconducter (v.3.1.3). Missing rsids were obtained, duplicate and multi-allelic 157

variants excluded, and alleles aligned to the reference, flipping effect and frequency
direction accordingly. Where necessary, MungeSumstats was used to lift over
genome build coordinates from GRCh38 to GRCh37 via the UCSC Genome Browser
chain file.

162

163 2.2 Mendelian randomisation

164 2.2.1. Metabolite instrument selection

Independent instrumental variables (IVs) were initially selected at genome-wide 165 significance ($p \le 5 \ge 10^{-8}$), clumping at an r² threshold of 0.001 within 10,000 kb of the 166 167 lead variants. Clumping was conducted using the ieugwasr package (v.0.1.4), PLINK (v.1.9)⁶¹ binaries and the European sample of the 1000 Genomes phase 3 reference 168 169 panel⁶² (N = 503), restricted to minor allele frequency (MAF) > 0.01. This is the same used 170 reference panel by the MRC IEU **OpenGWAS** database⁶³ 171 (http://fileserve.mrcieu.ac.uk/ld/1kg.v3.tgz).

Where less than five IVs were available for any given exposure, a lower p-value 172 threshold of 5 x 10⁻⁶ was used for IV selection as per previous analyses⁶⁴. If less than 173 174 5 IVs were available at the 5 x 10⁻⁶ threshold, this metabolite was excluded. Where an 175 IV was not available for the outcome, proxy IVs (i.e., variants in linkage disequilibrium (LD) with the original instrument at $r^2 > 0.8$) were identified using snappy (v.1.0) 176 177 (https://gitlab.com/richards-lab/vince.forgetta/snappy) and same reference panel. Proxies were selected using the highest r² value and closest genomic position. Prior 178 179 to analysis, exposure and outcome were harmonised to the same effect allele, and strand ambiguous palindromic variants (MAF > 0.42) dropped. Instrument strength 180 was assessed via their F-statistic ($\beta_{exposure}^2/SE_{exposure}^2$), with weak instruments (F-181 statistic < 10) excluded. If less than 5 IVs remained, the metabolite was again 182 183 excluded. Instrument measurement error was assessed with the I²_{G-X} statistic (< 0.9 suggestive of measurement error)⁶⁵. 184

Following the above steps the effects of 428 meta-analysed metabolites were
tested, plus 740 and 132 metabolites from the CLSA and NIHR UK Bioresource
studies, respectively, for a total of 1300 unique metabolites/metabolite ratios.

188

189 2.2.2. MR analyses

We conducted the primary analyses using inverse variance weighted MR (IVW-MR) with multiplicative random effects as recommended⁶⁶. If the IVW-MR estimate was statistically significant after Benjamini-Hochberg false discovery rate (FDR) correction⁶⁷ ($p_{FDR} \le 0.05$, corrected for total number of tests *specific to each* outcome), six sensitivity analyses were conducted to assess its robustness to violations of the pleiotropy assumption and instrument validity. We implemented methods that assume

a majority valid instruments (weighted median⁶⁸; penalised weighted median⁶⁹), 196 197 plurality valid instruments (constrained maximum likelihood (cML)⁷⁰; contamination 198 mixture model MR (MR-ContMix)⁷¹), and that exclude invalid outliers (MR-Lasso⁷²). 199 Additionally, we used MR-Egger⁷³, which gives consistent causal estimates even if all 200 instruments are not valid, provided pleiotropic effects are not correlated with variantexposure associations. This is known as the Instrument Strength Independent of 201 202 Direct Effect (InSIDE) assumption and is MR-Egger-specific. To pass sensitivity 203 criteria, all sensitivity analysis point estimates needed to be directionally concordant 204 with the IVW estimate and the majority (≥ 4) statistically significant at $\rho \leq 0.05$. Where 205 a metabolite passed sensitivity criteria, we performed reverse IVW-MR as above with 206 the outcome as the exposure.

207 Pleiotropy was assessed using the MR-Egger intercept test (no evidence of 208 pleiotropy: $p_{Eager-Intercept} \ge 0.05$) and heterogeneity using Cochran's Q (no evidence of 209 heterogeneity: $p_{Q-Stat} \ge 0.05$). Metabolites passing sensitivity were further inspected 210 using leave-one-out (LOO) analysis to assess whether causal estimates were driven by the inclusion of a single influential variant. Metabolites that passed sensitivity 211 212 criteria and had no LOO outlier variant were considered polygenic metabolites and 213 are referred to as such henceforth. Those passing sensitivity but with a LOO outlier 214 variant were considered single instrument metabolites.

215

216 2.2 Further analysis of polygenic metabolites

217 2.3.1 Conditional analysis

Hysi et al.⁵⁹ noted that many metabolites are genetically correlated with phenotypes related to body composition and educational level. To assess whether any identified effects were driven in part by the genetic correlations between the metabolites and these phenotypes, we performed conditional GWAS of the neuropsychiatric disorders using multi-trait conditional and joint analysis (mtCOJO)⁷⁴ to remove the per-SNP effects of body mass index (BMI), BMI-adjusted waist-to-hip ratio (WHR), and educational attainment (EA).

We obtained GWAS summary statistics for BMI (N = 806,834) and BMIadjusted waist-to-hip ratio (N = 697,734) from the GIANT consortium^{75,76}. We additionally obtained summary statistics for educational attainment (EA) from the EA4 GWAS meta-analysis, excluding 23andMe, from the Social Science Genetic Association Consortium (SSGAC)⁷⁷ (N = 765,283).

IVW-MR estimates were recalculated for significant metabolite neuropsychiatric disorder pairs post-mtCOJO and compared to the original
 estimates. Forest plots were visually inspected for evidence of attenuation between
 original and adjusted estimates.

234

235 2.3.2 Metabolite prioritisation using MR-BMA

236 Metabolites are highly genetically correlated⁵⁸. Consequently, univariate MR 237 estimates - which assume exposures are independent - may be biased by the pleiotropic effects of other risk metabolites. Such issues may be addressed using MR 238 with Bayesian model averaging (MR-BMA)⁷⁸. MR-BMA is a multivariable MR 239 approach that ranks of causal effects among related exposures according to their 240 241 independent causal signal. Unlike conventional multivariable MR methods, MR-BMA 242 is well suited for the highly correlated nature of high-throughput exposures such as metabolites⁷⁸. Instruments were selected by pooling those used in IVW-MR for all per-243 disorder statistically significant metabolites, excluding correlated instruments as 244 245 before $(r^2 > 0.001$, window = 10,000 kb). We use a prior probability of 0.1 and a prior variance of 0.25 as previously^{78,79}. Metabolites were ranked according to their 246 247 marginal posterior probability (MIP), with MIP ≥ 0.1 interpreted as causal. To avoid 248 multicollinearity between the exposures, we calculated a genetic correlation matrix using the linkage disequilibrium score regression (LDSC)⁸⁰ function 249 of 250 GenomicSEM⁵⁶. As per the original MR-BMA study, where point estimates \geq 0.95, we 251 excluded the metabolite correlated with the most other metabolites (if > one) or 252 retained only the metabolite with the most-significant IVW-MR estimate in the MR-253 BMA analysis (if only one).

254

255 2.3.2 Cross-trait polygenic score (PGS) analysis

256 To assess whether any of the polygenic metabolites prioritised in MR-BMA be used for disease prediction, we calculated polygenic scores (PGS) - the weighted sum of 257 258 an individual's risk alleles⁸¹ – within the reference standardised framework of the GenoPred pipeline⁸² using individual level data from the UK Biobank (UKB)⁸³. Within 259 GenoPred, allele weights were calculated using MegaPRS⁸⁴, a PGS method that uses 260 261 the BLD-LDAK heritability model and improves prediction by incorporating 262 information on allele frequency, LD and various functional annotations. MegaPRS has shown strong predictive performance compared to other PGS methods^{85,86}. 263

264 UKB participants were excluded from analyses if they had unusual levels of 265 heterozygosity, a call missing rate >2% or discordant phenotypic and genetic sex (F_X 266 < 0.9 for males, $F_X > 0.5$ for females). Individuals were filtered for relatedness up to 267 3^{rd} degree relatives based on KING kinship estimates (r < 0.044)⁸⁷ using 268 GreedyRelate (v1.2.1) to remove one individual from each related pair, maximising sample size (https://gitlab.com/choishingwan/GreedyRelated). Analyses were 269 270 restricted to individuals of European ancestry. The final sample contained 381,564 271 individuals prior to any age-based exclusions.

Case/control status was defined using the first occurrence data fields from the 272 273 UKB (Supplementary Table 3), where cases were ascertained using primary care 274 Read v2 or Read CTV3 codes, hospital inpatient ICD-9 and ICD-10 codes, death 275 record ICD-10 codes and medical condition codes self-reported at UKB assessment 276 centre visits. Individuals were excluded if the code had no event date or if the date 277 of event was before, the same year as or on the participants date of birth, or a date 278 in the future. Associations between metabolite-PGS and respective neuropsychiatric 279 disease was assessed using logistic regression, controlling for age, sex, genotyping 280 batch, assessment centre and the first ten genetic principal components from the 281 UKB. Within each model, the comparison group was restricted to individuals with no occurrence of any of the neuropsychiatric disorders. To provide age-appropriate 282 283 controls for AD and PD, samples were restricted for those analyses to individuals 284 aged ≥60 and ≥50 years, respectively. For DEP and ANX cases, individuals with an 285 occurrence of BP or SCZ were excluded. The variance explained by each PGS was assessed using Nagelkerke's pseudo-r². Sample sizes ranged from 140,154 to 286 287 356,763, depending on the disorder, with case numbers ranging from 600 (ALS) to 46,900 (DEP) (mean age range = 56.65-64.13; %male range = 46.32-49.35). 288

- 289
- 290

2.4 Further analysis of single instrument metabolites

291 2.4.1 Statistical colocalisation

292 Using LOO analysis, we identified IVs that significantly attenuated the IVW-MR 293 estimate when excluded. We extracted regions +/- 250 kb of these IVs and performed 294 statistical colocalisation for each metabolite and the respective neuropsychiatric disorder within the COLOC-reporter pipeline⁸⁸. Regions of interest were extracted and 295 296 harmonised for each phenotype to contain only shared variants on the reference 297 panel. Colocalisation was performed using the *coloc.abf* function of the COLOC 298 package⁸⁹. A posterior probability of 0.8 for hypothesis four (PP.H₄) – presence of a shared causal variant between the phenotypes - was taken as evidence of 299 colocalisation (PP.H₄ \ge 0.6 taken as suggestive). 300

301

302 2.4.2 eQTL colocalisation

For regions of colocalisation (including suggestive), we identified genes located within 10 kb of credible SNPs using Ensembl and biomaRt (v.2.54.0). For each gene, we extracted *cis*-eQTLs from the whole blood eQTL summary data of the eQTLGen Consortium⁹⁰ (N= 31,684) and performed colocalisation between the eQTLs and both phenotypes in each metabolite-neuropsychiatric disorder pair as above.

310 2.4.2 eQTL MR

For genes colocalising with both the metabolite and neuropsychiatric disorder a trait-311 312 pair, we extracted independent instruments for gene expression from the eQTL summary statistics ($p \le 5 \ge 10^{-8}$; $r^2 \le 0.001$; window = 10,000 kb) and used IVW-MR 313 to assess the causal effect of gene expression levels on the outcome and exposure. 314 We examined the consistency of the gene expression causal effects using Summary-315 based Mendelian Randomisation (SMR)⁹¹, extracting eQTL probes for the relevant 316 gene from blood-based eQTL summary datasets from Westra et al.⁹² (N = 3,511) and 317 318 Lloyd-Jones et al.⁹³ (N = 2,765). Heterogeneity was assessed using the HEterogeneity In Dependent Instruments (HEIDI) test, with p_{HEIDI} < 0.05 indicative of 319 320 heterogeneity. This is essentially a test of colocalisation.

Previous research has indicated that the causal effect of gene expression on a complex trait can be mediated by the effect of metabolites within a transcriptmetabolite-trait causal triplet⁹⁴. Where gene expression levels showed a significant causal effect on both an outcome and a metabolite, we calculated the proportion mediated using the product of coefficients method as per previous analyses⁹⁵. Standard errors were estimated using the delta method and *p*-values drawn from a z-score distribution.

328

329 3. Results

330 3.1 Mendelian randomisation

331 We conducted a total of 10,327 tests of the causal effect of the metabolites and ratios 332 on the eight neuropsychiatric outcomes (instrument N-range: 5-27). Of these, 1695 tests were conducted with instruments clumped at 5 x 10⁻⁸ and 8632 with instruments 333 clumped at 5 x 10⁻⁶. For single instruments, F-statistics ranged from 10.11 to 5625.88 334 335 (mean per-test F-statistics range: 20.77-1163.90). Analyses were thus not impacted by weak instruments. Per-test I²_{G-X} ranged from 0.45 to 1.000. Only 94 tests (0.009%), 336 involving 13 unique metabolites, were conducted with $I_{G-X}^2 < 0.9$, suggestive of 337 338 measurement error. Only 27 tests were conducted using instruments with $I_{G-X}^2 \leq 0.8$, 339 involving six metabolites: 2-hydroxyarachidate, 4-hydroxy-2-oxoglutaric acid, 4-340 vinylguaiacol sulphate, glycolithocholate, and O-cresol sulphate.

Primary IVW-MR analyses identified 138 causal effects involving 113 unique metabolites after outcome-specific FDR correction (**Supplementary Table 4**; Figure 2a). Of these, 85 metabolite-outcome pairs passed our sensitivity criteria, involving 77 unique metabolites (**Supplementary Table 5**). All neuropsychiatric disorders had two or more metabolites with statistically significantly effects. No reverse effects were detected for these metabolite-outcome pairs after FDR-correction (**Supplementary Table 6**). IVW-MR odds ratios (OR) for metabolite-neuropsychiatric disorder trait-

pairs ranged from 0.73 to 1.48 (*p*-value range: $1.52 \times 10^{-3} - 9.67 \times 10^{-31}$; *p*_{EDB} range: 348 349 4.45 x 10⁻² - 1.26 x 10⁻²⁷). However, MR-Egger intercept tests detected significant 350 pleiotropy for eight of the 85 metabolite-outcome pairs ($p_{Equer-Intercept} < 0.05$) 351 (Supplementary Table 7). Cochran's Q heterogeneity tests detected significant 352 heterogeneity for 15 ($p_{Q-Stat} < 0.05$) (Supplementary Table 8). All metabolite-outcome pairs with $p_{Eager-Intercept} < 0.05$ and 14 out of 15 with $p_{Q-Stat} < 0.05$ were identified as 353 influenced by single influential variants in the LOO analysis (Supplementary Table 354 355 **9**). Only the effect of the ratio of mannose to glycerol on depression ($p_{Q-Stat} = 0.043$) 356 was not driven by a single influential variant.

Excluding metabolites with effect estimates primarily influenced by single 357 variants left a total of 41 metabolite-neuropsychiatric disorder trait-pairs with 358 polygenic metabolites - all unique. Of these, 13 were identified with depression, 359 360 seven with MS, six with ALS, four each with AD and bipolar disorder, three with 361 schizophrenia, and two each with anxiety and PD (Figure 2b). These metabolites 362 were linked to nine broad metabolic classes (super-pathways), counting the combinations of pathways of metabolite ratios as unique pathways (Figure 2b; 363 364 Supplementary Table 10). Over half (N = 22) were lipids, and the rest amino acids (N = 10), nucleotides (N = 3), peptides (N = 1), carbohydrates (N = 1) or ratios 365 involving amino acid/cofactors and vitamins (N = 1), amino acid/energy (N = 1) and 366 carbohydrate/lipid (N = 1) pathways. The remaining metabolite – glutamine conjugate 367 of C6H10O2 (2) - is considered only partially characterised. 368

These metabolites were implicated in 28 unique sub-pathways representing 369 370 the metabolic/biochemical subclasses related to the metabolites (Figure 2c; 371 Supplementary Table 10). The largest group of metabolites was related to sphingolipid metabolism (N = 5). All metabolites involved in sphingolipid metabolism 372 had effects on psychiatric disorder risk. Sphingosine 1-phosphate has a risk 373 374 increasing effect on bipolar disorder (OR [95%CI] = 1.17 [1.06-1.28], p-value = 9.49 375 $\times 10^{-4}$, $p_{FDR} = 0.03$), while glycosyl-N-stearoyl-sphingosine (d18:1/18:0), 376 sphingomyelin (d18:1/24:1, d18:2/24:0) and sphingomyelin (d18:2/23:0, d18:1/23:1 and d17:1/24:1) has risk decreasing effects on depression (OR range: 0.93-0.96, p-377 value range: 2.38 x 10^{-4} - 9.91 x 10^{-4} ; p_{FDR} range: 0.02-0.04). Additionally, 378 sphingomyelin (d18:1/18:1, d18:2/18:0) has a risk decreasing effect on schizophrenia 379 380 $(OR [95\%CI] = 0.87 [0.81-0.94], p-value = 1.89 \times 10^{-4}, p_{FDR} = 0.04).$





383

384

385 Figure 2: (a). Volcano plots for anxiety (ANX), bipolar disorder (BP), depression (DEP), schizophrenia 386 (SCZ), Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS) and 387 Parkinson's disease (PD) showing odds ratios and -log₁₀ p-values from inverse variance weighted 388 Mendelian randomisation (IVW-MR) for all tested metabolites. (b). Forest plot of FDR statistically 389 significant metabolites associated with neuropsychiatric outcomes in IVW-MR and passing sensitivity 390 tests, with no leave-one-out (LOO) outliers (i.e., polygenic metabolites). Point estimates indicate odds 391 ratios with bars representing 95% confidence intervals (95%CI). Point estimates for each metabolite 392 are coloured according to their metabolic super-pathway. (c). Stacked histograms showing total count 393 of FDR statistically significant polygenic metabolites associated with each neuropsychiatric disorder, 394 with fill colours indicating metabolite sub-pathways. AD = Alzheimer's disease; ALS = Amytropic 395 Lateral Sclerosis; ANX = anxiety; BP = Bipolar Disorder; DEP = Depression; MS = Multiple Sclerosis; PD = Parkinson's disease; SCZ = Schizophrenia 396

397

The strongest negative effect was observed for the amino acid leucine and PD (OR [95%CI] = 0.73 [0.62-0.85], $p = 9.64 \times 10^{-5}$; $p_{FDR} = 3.13 \times 10^{-2}$). Isoleucine showed similar effects (OR = 0.73 [0.62-0.86]; $p = 1.65 \times 10^{-4}$; $p_{FDR} = 4.28 \times 10^{-2}$). The strongest positive effect was observed for the lipid 1-(1-enyl-oleoyl)-GPE (P-18:1) and MS (OR 402 = 1.48 [1.33-1.65]; *p*-value = 2.71 x 10⁻¹²; p_{FDR} = 3.42 x 10⁻⁹). The most statistically 403 significant effect was identified for the ratio of arachidonate (20:4n6) to oleate to 404 vaccenate (18:1) and anxiety (OR = 0.93 [0.93-0.95], *p*-value = 9.67 x 10⁻³¹, p_{FDR} = 405 1.26 x 10⁻²⁷).

406 The remaining 44 metabolite-neuropsychiatric disorder trait-pairs had attenuated effects in the LOO analysis, involving 36 unique metabolites and six of the 407 neuropsychiatric outcomes (Supplementary Table 11). Most of the effects were 408 409 observed in relation to psychiatric disorders (N = 40), primarily with BP (N = 16) and 410 DEP (N = 16). Another four were observed with ANX and three with SCZ. These 411 metabolite-psychiatric trait-pairs involved 33 unique metabolites, 25 of which were lipids and one a ratio of lipid/carbohydrate. These lipids were involved in 12 unique 412 413 sub-pathways, the largest group of which was related to phospholipid metabolism (N 414 = 6). The remainder were amino acids (N = 5), a carbohydrate (N = 1) and a 415 xenobiotic (N = 1), involved in seven unique sub-pathways. Of those remaining, four 416 unique single instrument metabolites had a causal effect AD - two amino acids and 417 two xenobiotics - and a nucleotide showed causal effect on MS.

418 A total of 31 of the LOO associations were driven by 11 influential variants on 419 chromosome 11 within a ~500 kb window (61293499-61854782 bp). This region 420 contains the fatty acid desaturase (FADS) gene cluster, which is linked to the 421 regulation of fatty acid levels and their circulation⁹⁶. All metabolites influenced by 422 these variants were lipids and associated with psychiatric disorder risk ($N_{ANX} = 4$, N_{BP} 423 = 13, N_{DEP} = 12 and N_{SCZ} = 2). Between-variant LD estimates for the influential 424 instruments in this region were calculated using LDlinkR (v.1.3)⁹⁷ and ranged from 425 0.16-1, with $r^2 \ge 0.72$ for all variants except rs14570 and rs2524299 which showed a 426 maximum r² of 0.34 and 0.38, respectively (Figure 3a; Supplementary Table 12).

427 We used Wald ratio tests to re-estimate the effect of single instrument 428 metabolites on the relevant outcome using the influential instrument only. F-statistics 429 ranged from 105.37 to 5625.88. Wald estimates were directionally consistent with 430 IVW-MR estimates and remained significant at $p \leq 0.05$, although the protective effects of 4-guanidinobutanoate and mannonate on AD were only nominally 431 432 significant (p = 0.04 and 0.02, respectively) (Figure 3b; Supplementary Table 13). 433 Regions containing influential instruments were further investigated using 434 colocalisation.



436

Figure 3: (a). The r² estimates between influential single variants on chromosome 11 alongside their
genomic location. (b). Recalculated Wald ratio estimates for metabolites with influential single variants
using the influential variant only. Point estimates indicate odds ratios with bars representing 95%
confidence intervals (95%CI). Point estimates for each metabolite are coloured according to their
metabolic super-pathway. AD = Alzheimer's disease; ANX = anxiety; BP = Bipolar Disorder; DEP =
Depression; MS = Multiple Sclerosis; SCZ = Schizophrenia

443

3.2 Further analysis of polygenic metabolites

445 3.2.1 Conditional analysis

446 Conditioning neuropsychiatric outcomes on BMI, BMI-adjusted WHR or EA did not 447 attenuate the IVW-MR effect estimates for causally associated metabolites when re-448 estimated (**Supplementary Table 15; Supplementary Material 3**). This suggests that 449 the metabolite associations were not influenced by any correlation between the 450 genetic instrument's effect and the effects of these traits as captured in the 451 neuropsychiatric GWAS.

452

453 3.2.2 Metabolite prioritisation using MR-BMA

454 Prior to the per-outcome multivariate MR modelling in MR-BMA, we excluded the less

statistically significant of any metabolite pair correlated $\ge 95\%$ (Supplementary Table

15). As such, we excluded 5-methylthioadenosine (mta) from the AD model due to its

model due to its correlation with N-formylmethionine and uridine, 2-myristoyl-GPC
(14:0)* from the ALS model due to its correlation with 1-stearyl-GPC (O-18:0)* and the
glutamine to alanine ratio from the DEP model due to its correlation with gammaglutamylglutamine.

For AD, anxiety, MS, PD and schizophrenia, all metabolites had MIPs \geq 0.1, 462 suggesting unique causal contributions to risk. For bipolar disorder, sphingosine 1-463 464 phosphate, the ratio of histidine to phosphate and the ratio of glycine to pyridoxal 465 passed the MIP threshold, with 3-hydroxy-5-cholestenoic acid just under (MIP = 466 0.098). However, of the 12 metabolites included for depression, only the two 467 sphingomyelins (d18:1/24:1, d18:2/24:0 and d18:2/23:0, d18:1/23:1, d17:1/24:1) and 1-(1-enyl-palmitoyl)-2-arachidonoyl-GPC (P-16:0/20:4) passed. For ALS, only 468 acetylcarnitine passed the MIP threshold. Acetylcarnitine had the highest overall MIP 469 470 of all metabolites tested (MIP = 0.893) (Supplementary Table 16).

471

472 3.2.3 Polygenic score (PGS) analysis

No MR-BMA prioritised metabolite PGS was associated with any of their respective 473 474 outcomes after FDR correction for 23 tests ($p_{FDR} \ge 0.05$). Nominal associations were 475 observed between depression and the PGS for sphingomyelin (d18:2/23:0, 476 d18:1/23:1, d17:1/24:1) and 1-(1-enyl-palmitoyl)-2-arachidonoyl-GPC (P-16:0/20:4) 477 with identical effect sizes (OR[95%CI] = 0.989 [0.979-0.998], *p*-value range = 2.131 x 10^{-2} - 2.517 x 10^{-2}) and between the PGS for leucine and PD (OR [95%CI] = 0.962 478 479 [0.93-0.996, p-value = 2.814×10^{-2}). These effects were directionally consistent with the MR estimates but had non-relevant predictive ability given small Nagelkerke's 480 pseudo-r² estimates (Nagelkerke's pseudo-r²_{MAX} = 1.445×10^{-4}) (Supplementary 481 Table 17). 482

483

484 3.3 Further analysis of single instrument metabolites

485 3.3.1 Colocalisation at loci of influential instruments

486 Of the 44 colocalisation tests conducted in regions +/- 250 kb of the LOO influential variants, 26 showed evidence of colocalisation (PP.H₄ \ge 0.8) and a further five had 487 488 suggestive evidence (PP.H₄ \ge 0.6) (Supplementary Table 18). All except one of these regions were on chromosome 11 within a ~500 kb window (61293499-61854782 bp). 489 490 All disorders colocalising with metabolites in this region were psychiatric and every psychiatric disorder examined showed colocalisation with at least one metabolite. 491 492 Colocalisation has been previously observed between the omega-3 fatty acid 493 docosahexaenoic acid (DHA) and depression within the same region³⁹.

494 All implicated metabolites except 1-stearoyl-2-docosapentaenoyl-GPC 495 (18:0/22:5n6)* were complex fatty acid chains containing the fatty acids arachidonic

acid (AA) (N = 18), linoleic acid (LA) (N = 5), alpha-linolenic acid (ALA) (N = 1) or 496 497 both AA and LA (N = 4). Higher levels of AA-containing metabolites were consistently 498 protective in Wald estimates while higher levels of LA- or ALA-containing metabolites 499 had risk increasing effects. Where ratios contained both AA- and LA-containing 500 metabolites, higher levels of the AA relative to the LA was protective and higher LA metabolites relative to the AA risk increasing (Supplementary Table 19). This is 501 502 concordant with previous metabolome-wide MR analysis of bipolar disorder⁴¹ and 503 observational analysis of depression⁹⁸. The other region of colocalisation was 504 identified on chromosome 12 (56615338-57115338) between the ratio of histidine-to-505 glutamine and AD (PP.H₄ = 0.92).

506 Two tests showed evidence of two distinct causal variants at the tested locus 507 - the ratio of glucose to mannose and depression (chr2: 27480940-27980940; PP.H3 508 = 0.92) and docosapentaenoate (n6 DPA; 22:5n6) and bipolar disorder (chr11: 509 61347212-61847212; PP.H₃ = 0.99). Suggestive evidence for two distinct causal 510 variants was also identified for butyrylglycine and depression (chr12:120925524-121425524; PP.H₃ = 0.70), methylsuccinate and depression (chr12:120926083-511 512 121426083; PP.H₃ = 0.63), and 5-methyluridine (ribothymidine) and MS (Chr22:50687969-51187969; PP.H₃ = 0.63). PP.H₃ \ge 0.6 in these regions suggests 513 514 that MR estimated effects arose from linkage disequilibrium, violating MRs horizontal pleiotropy assumption. Remaining colocalisation tests were inconclusive. 515

516

517 3.3.2 eQTL colocalisation

In total, nine genes were identified within 10 kb of credible SNPs at colocalising loci 518 519 (Supplementary Table 20). For the colocalisation analyses at chr11:61293499-61854782, eQTLs for MIR611 or MIR1908 were not available in the eQTLGen 520 521 summary statistics. As such, follow-up eQTL colocalisation in this region was 522 conducted only with MYRF, TMEM258, FEN1, FADS2 and FADS1. For the region 523 chr12:56615338-57115338, eQTLs were not available for *MIP*, but were available for 524 GLS2 and SPRYD4. In total, 130 colocalisation tests were conducted with eQTLs. Of these, only eQTLs for SPRYD4 colocalised with both a risk metabolite and its 525 526 respective neuropsychiatric outcome: the ratio of histidine-to-glutamine (PP.H₄ = 527 0.91) and AD (PP.H₄ = 0.91). Additional colocalisation was identified for *GLS2* with 528 the ratio of histidine-to-glutamine (PP.H₄ = 0.99), but not AD (PP.H₄ = 0.42). *TMEM258* 529 colocalised with depression (PP.H₄ = 0.86). Suggestive colocalisation was identified 530 between *TMEM258* and anxiety and between *MYRF* and depression (PP.H₄ \ge 0.6). Of 531 the remaining tests, 113 indicated two distinct causal variants in the region (PP.H₃ \geq 532 0.8), four were suggestive of only a causal variant for gene expression, and the 533 remainder inconclusive (Supplementary Table 21). 534

535 3.3.3 eQTL MR for the histidine to glutamine ratio and AD

We conducted MR analyses for the effect of SPRYD4 expression levels on the ratio 536 537 of histidine-to-glutamine and AD using five independent instruments. SPRYD4 expression levels were identified as increasing risk for AD (OR = 1.08 [1.02-1.16], β 538 [95%CI] = 0.08 [0.02-0.15], *p*-value = 0.007) and the level of the ratio of histidine to 539 glutamine (β [95%CI] = 0.30 [0.18-0.42], *p*-value = 1.16 x 10⁻⁶). SMR estimates for 540 the effect of SPRYD4 expression were directionally consistent and statistically 541 significant at $p \le 0.05$ for AD and the ratio of histidine-to-glutamine across eQTL 542 543 panels. HEIDI tests did not indicate heterogeneity ($p_{HEIDI} \ge 0.05$) (Supplementary Table 22). There was no evidence that the ratio of histidine to glutamine substantially 544 545 mediates the effect of SPRD4 expression on AD, with only a nominally significant association and wide confidence intervals (proportion mediated [95%CI] = 63.20% 546 [1.80-124.59%], *p*-value = 0.043). 547

548

549 3.6 Further examination of histidine, glutamine, AD and SPRYD4

To further evaluate the association between the ratio of histidine to glutamine, we re-550 examined the IVW-MR estimates for the separate effects of histidine and glutamine 551 552 on AD. No causal effect was observed for histidine on AD, not even nominally (OR = 1.11 [0.99-1.27], $\beta = 0.11$ [-0.011-0.24], *p*-value = 0.07). However, there was a 553 nominally significant negative causal effect for glutamine (OR = 0.87 [0.81-0.94], β 554 [95%CI] = -0.14 [-0.21 to -0.06], *p*-value = 0.0007, *p*_{FDR} = 0.052). Although glutamine 555 passed post-hoc sensitivity criteria with no evidence of pleiotropy or heterogeneity 556 557 (Supplementary Table 23), LOO identified the same influential variant on chromosome 12 as observed for the ratio of histidine-to-glutamine - the 3'-UTR 558 variant rs2657879 (Supplementary Table 24). For glutamine, the effect of rs2657879 559 560 was in the opposite direction to the histidine-to-glutamine ratio.

561 A Wald ratio test using only this instrument estimated a negative effect of glutamine on AD risk (OR = 0.84 [0.76-0.91], β = -0.19 [-0.28 to -0.09], p-value = 9.65 562 x 10⁻⁵). Strong evidence of colocalisation was observed between glutamine and AD 563 in the region (PP.H₄ = 0.92), and between glutamine and *SPRYD4* (PP.H₄ = 0.98) 564 (Supplementary Table 25). Gene expression levels of SPRYD4 were negatively 565 associated with glutamine in the MR analysis ($\beta = -0.35$ [-0.52 to -0.18], p-value = 566 3.94 x 10⁻⁵). Strong, directionally consistent effects of *SPRD4* expression on glutamine 567 were observed in SMR (Supplementary Table 26). However, the HEIDI tests 568 indicated heterogeneity ($p_{HEIDI} \leq 0.05$). There was no evidence that glutamine 569 mediated the effects of SPRD4 expression on AD (proportion mediated [95%CI] = 570

- 571 75.81% [-0.36-151.99%], *p*-value = 0.051). LocusZoom plots for the ratio of histidine
- to glutamine, glutamine, AD and *SPRYD4* gene expression are shown in Figure 4.



574 Figure 4: LocusZoom plots of the colocalising region ($PPH_4 \ge 0.8$) chr12: 56615338-57115338 for **575** Alzheimer's disease, the ratio of histidine to glutamine, glutamine, and SPRYD4 expression.

576 4. Discussion

We identified 77 unique plasma metabolites and a total of 85 sensitivity robust MR 577 578 estimated causal effects on neuropsychiatric disorder risk. Over half of associations 579 were driven by single influential variants. Of these, 30 metabolite-neuropsychiatric 580 disorder trait-pairs had greater than suggestive colocalisation and 29 were lipids 581 colocalising with a psychiatric disorder near the FADS gene cluster on chromosome 11. No eQTL colocalisation was observed for any metabolite-outcome trait-pair in this 582 583 region, suggesting the underlying mechanisms are not related to shared gene expression effects. Additional colocalisation was observed between AD glutamine-584 585 related metabolites and SPRYD4 gene expression on chromosome 12. For the 586 remaining 41 polygenic metabolites, multivariate analysis with MR-BMA prioritised 23 metabolites and implicated sphingolipids and carnitine derivatives in psychiatric and 587 588 neurodegenerative risk respectively. However, the predictive performance of 589 metabolite polygenic scores was negligible in the UK Biobank.

590 Lipids - specifically polyunsaturated fatty acids (PUFAs) - have previously shown MR causal effects on depression, with docosahexaenoic acid (DHA) 591 colocalising at the FADS gene cluster³⁹. Our study highlights the broader significance 592 593 of this region in linking lipid levels to risk across the psychiatric disorder spectrum. 594 Here, we identify suggestive colocalisation between at least one lipid and every examined psychiatric disorder. Nearly all lipids colocalising with psychiatric 595 596 disorders contained linoleic acid (LA) or arachidonic acid (AA) - both omega-6 597 PUFAs. AA-containing lipids were consistently protective, while LA-containing lipids 598 increased risk. These findings are consistent with other MR studies of bipolar disorder, depression and schizophrenia^{41,99,100}. Our results suggest that these 599 associations extend to ANX. Although these effects were primarily driven by shared 600 601 causal variants on chromosome 11, several polygenic metabolites comprised of 602 AA/LA-containing lipids also showed causal effect on psychiatric risk. The ratio of 603 arachidonate (20:4n6)-to-oleate-to-vaccenate (18:1) and 1-(1-enyl-palmitoyl)-2arachidonoyl-GPC (P-16:0/20:4) - both AA-containing - had risk decreasing effects 604 605 on anxiety and depression respectively and were prioritised in multivariate analysis. 606 In single instrument analyses, this ratio had risk decreasing effects on bipolar 607 disorder, depression and schizophrenia, colocalising with all. These results suggest 608 that effects of AA/LA-containing lipids in psychiatric risk may extend beyond effects 609 on chromosome 11.

610 Circulating levels of lipids containing LA and AA may be promising intervention 611 targets for psychiatric disorders. LA – the most abundant omega-6 PUFA in the 612 western diet – is found in nearly all manufactured food through vegetable oils¹⁰¹, while 613 AA is found in animal products such as meat, poultry, fish and eggs¹⁰². As free fatty acids AA is a downstream product of LA, from which it is synthesised through
desaturation and chain elongation¹⁰² (Supplementary Material 4).

616 Free LA and AA are linked to inflammatory dysregulation¹⁰³ – itself implicated in psychiatric disorders^{104,105}. AA is catalysed by cytochrome P450 enzymes to 617 epoxyeicosatrienoic acids (EETs), which show anti-inflammatory effects and are 618 suggested to be protective of neurological function¹⁰⁶. The deleterious effects of LA-619 620 containing lipids compared to the protective effects of AA-containing lipids may 621 implicate dysregulated conversion from LAs to AAs, contributing to elevated 622 inflammation as less AA is available for conversion to anti-inflammatory EETs. 623 However, LA-to-AA conversion is relatively low in humans and requires LA to be in 624 free form following cleavage from lipid molecules via enzymes such as phospholipase A2 (PLA2). Although PLA2 action on fatty acids has been previously 625 626 linked to inflammatory depression¹⁰⁷, further investigation is required to elucidate 627 mechanisms by which LA- and AA-containing lipids contribute to psychiatric risk.

628 The effects of the ratio of histidine-to-glutamine and glutamine on AD observed here are in line with previous MR evidence suggesting higher blood glutamine as 629 protective^{37,108}. Interestingly, glutamine is noted to exert a neuroprotective effect 630 631 against β -amyloid aggregation¹⁰⁹ – a key drug target for AD¹¹⁰. This study provides further evidence for its protective effects on AD risk and suggests the association is 632 driven by shared causal variants on chromosome 12. Further, we observe that the 633 634 association between AD and glutamine may be partially driven by the mutual effect 635 of SPRYD4 gene expression. As SPRYD4 has not been previously identified in AD 636 GWAS it represents a novel locus of interest for future study.

637 Our study also provides further evidence for the role of sphingolipid metabolism in psychiatric disorders. Sphingolipids are fatty acids with roles in cell 638 639 growth/death, inflammation, mitochondrial function and immune response¹¹¹. We 640 identified two sphingomyelins and glycosyl-N-stearoyl-sphingosine (d18:1/18:0) as 641 protective for depression, with the sphingomyelins both prioritised in multivariate 642 analysis. Further, sphingomyelin (d18:1/18:1, d18:2/18:0) was protective for schizophrenia and sphingosine-1-phosphate indicated to elevate risk of bipolar 643 644 disorder. Sphingomyelins are central to ceramide metabolism, to which they are 645 converted via sphingomyelinase and back via sphingomyelin synthase¹¹² 646 (Supplementary Material 5). Ceramides are catabolised into sphingosine and eventually sphingosine-1-phosphate¹¹². General dysfunction of sphingolipid 647 metabolism, particularly ceramide aggregation, has been previously observed in 648 psychiatric disorders^{23,24,111,112} and reduced sphingomyelin levels may contribute to 649 650 elevated neuroinflammation¹¹². As such, the ceramide system is a proposed pathway 651 for drug-based interventions for psychiatric disorders¹¹². This study implicates 652 sphingomyelins as possible protective targets.

Although fewer metabolomic patterns were observed in neurodegenerative 653 654 disorders we did observe protective effects of several carnitine related metabolites -655 adipoylcarnitine for MS and acetylcarnitine and propionylcarnitine for ALS. All three 656 are metabolised from L-carnitine, which plays a role in the transportation of fatty acids 657 to mitochondria¹¹³, and when acetylated is suggested to slow disease progression for both disorders and AD¹¹⁴⁻¹¹⁶. Further, lower serum carnitine levels are observed in 658 659 ALS¹¹⁷ and are associated with increased fatigue in MS¹¹⁸. A randomised control trial 660 (RCT) of acetylcarnitine supplementation in ALS suggests it may improve selfsufficiency in patients compared to placebo¹¹⁴. The importance of acetylcarnitine for 661 662 ALS is further emphasised by our multivariate analysis, where it was the only metabolite prioritised for ALS and had the highest MIP of any metabolite examined. 663 664 Interestingly, a larger phase two/three RCT of acetylcarnitine effects on biological and 665 clinical outcomes in ALS is underway 666 (https://classic.clinicaltrials.gov/ct2/show/NCT06126315). The remaining polygenic 667 metabolites did not show clear functional relatedness, indicating disorder-specific metabolomic contributions - broadly confirmed in MR-BMA, where, for most 668 669 disorders, all metabolites had a MIP \geq 0.1, indicating unique causal effects.

- Although no specific metabolites were identified with an effect on both a psychiatric and neurodegenerative disorder, our results suggest the general importance circulating lipids in both categories. Dietary lipids are known to modulate neuroinflammation and play an important role in the brain by regulating neuronal and synaptic function¹¹⁹. Future studies exploring biological overlap in neuropsychiatric disorders may therefore wish to focus on lipidomic analysis for the purposes of further elucidating shared metabolic pathways.
- 677 Several disorder-specific metabolites warrant further discussion. For example, 678 we replicated the risk-increasing effect of uridine on MS previously identified 679 observationally and in MR^{40,120}. Uridine is linked to pyrimidine metabolism with 680 important biological functions including RNA synthesis and the regulation of glucose, lipid and amino acid levels¹²¹. Interesting, within pyrimidine biosynthesis, uridine is an 681 eventual metabolic product of dihydroorotate¹²¹, also identified here as increasing 682 683 risk for MS. Additionally, the branch chain amino acids (BCAAs) leucine and its 684 isomer isoleucine were both protective for PD. Plasma levels are noted to be lower in 685 cases than controls and correlated with increased functional disability¹²². In an RCT 686 of PD/parkinsonism, supplementation with leucine and vitamin D enriched whey 687 protein was significantly associated with increased lower body function and muscle mass retention¹²³. Our findings provide further evidence of the protective effects of 688 689 leucine/isoleucine in PD and suggest them as possible interventional targets.

690 In the UKB, PGS for prioritised polygenic metabolites showed limited 691 prediction of their respective outcome disorder. Polygenic scores are noted to explain only a small proportion of the variance even within the same phenotype¹²⁴. As such,
it is not entirely surprising that we are unable to detect significant associations crosstrait, particularly given the smaller effective target sample size available in the UKB
compared to the large, meta-analytic samples sizes available from GWAS summary
statistics for use in MR. To improve prediction, future studies might aggregate the
genetic effects of multiple metabolites to better capture the total underlying metabolic
risk for disease, for example through a multi-PGS framework¹²⁵.

699 In conclusion, we performed metabolome-wide MR to test the causal effects 700 of 1300 metabolites/metabolite ratios on eight neuropsychiatric disorders. Results 701 implicate AA and LA-containing lipids across the psychiatric disorder spectrum, with 702 shared causal variants identified near the FADS gene cluster. We also identified 703 shared causal variants between glutamine metabolites and Alzheimer's disease, and 704 identify a shared effect of SPRD4 gene expression. Additionally, our results implicate 705 sphingolipid metabolism in psychiatric disorders and carnitine related metabolites as 706 protective for MS and ALS, alongside several promising target metabolites with 707 disease-specific effects. More broadly, this study suggests that lipid metabolism 708 plays an important role in both psychiatric and neurodegenerative risk. The 709 metabolites identified in this study can help inform potential interventions and future, 710 targeted studies of metabolic contributions to disease risk.

711

712 5. Limitations

713 This study used data from individuals of European ancestry only and as such may lack generalisability. Further, as previously noted⁷⁹, although the exclusion of the 714 715 APOE region from the AD analyses is necessary to avoid violating MR assumptions, 716 this may result in false negatives due to the regions known role in lipid metabolism¹²⁶. 717 Conversely, we can have greater confidence that the metabolites identified here are 718 not confounded by APOE effects. Given the importance of this region in AD and lipid 719 metabolism, it deserves specific focus in future metabolomic work. Further, MR 720 requires that several assumptions - such the availability of suitable instruments and 721 absence of pleiotropic effects - be met to provide reliable results. Although we 722 mitigate against these by including only strong instruments (F-statistic \geq 10) and using a robust sensitivity criterion to delineate causal metabolites, results should be 723 724 interpreted with caution prior to further triangulation.

725

726 6. Funding and acknowledgements

LG is funded by the King's College London DRIVE-Health Centre for Doctoral Training
and the Perron Institute for Neurological and Translational. JM is supported by the
King's Prize Fellowship. This study has been partly delivered through the National

730 Institute for Health and Care Research (NIHR) Maudsley Biomedical Research Centre731 (BRC). PP is funded by an Alzheimer's Research UK Senior Research Fellowship.

This research has been conducted using the UK Biobank Resource under Application Number 82877. Ethical approval for the UK Biobank study has been granted by the National Information Governance Board for Health and Social Care and the NHS North West Multicentre Research Ethics Committee (11/NW/0382). Written informed consent was obtained from all participants by the UK Biobank. We thank the UK Biobank Team for collecting the data and making it available. We also thank the UK Biobank participants.

We also thank and acknowledge the contribution and use of the CREATE highperformance computing cluster at King's College London (King's College London.
(2022). King's Computational Research, Engineering and Technology Environment
(CREATE)).

743 We want to acknowledge the participants of the FinnGen study and the
744 veterans of the Million Veterans Project, as well as the research teams for both
745 studies.

For the purposes of open access, the author has applied a Creative Commons
Attribution (CC BY) license to any Accepted Author Manuscript version arising from
this submission.

749

750 **7. Data availability**

751 Data is available on reasonable request from the UK Biobank
752 (<u>https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/contact-us</u>).

753 Summary statistics from FinnGen are available online (https://www.finngen.fi/en/access results) and from the Million Veterans Project via 754 755 dbGaP request (https://www.ncbi.nlm.nih.gov/projects/gap/cgi-756 bin/study.cgi?studyid=phs001672.v1.p1).

GWAS summary statistics from the Psychiatric Genomics Consortium (PGC) 757 758 for Alzheimer's disease, anxiety, bipolar disorder, depression and schizophrenia are available from their website (https://pgc.unc.edu/for-researchers/download-results/). 759 760 Summary statistics for anxiety from iPSYCH are also available online (https://ipsych.dk/en/research/downloads). For Parkinson's disease and ALS, 761 762 GWAS summary statistics are available on Catalog at https://www.ebi.ac.uk/gwas/studies/GCST009325 763 and https://www.ebi.ac.uk/gwas/studies/GCST90027164 764 respectively. For multiple 765 sclerosis, summary statistics are available though the IEU Open GWAS Project (https://gwas.mrcieu.ac.uk/datasets/ieu-b-18/). Summary statistics for metabolites 766 al.58 GWAS 767 measured from Chen et are available on catalog

- (https://www.ebi.ac.uk/gwas/studies/) under accession numbers GCST90199621 90201020. Access to summary statistics for the metabolites measured by Hysi et al.⁵⁹
 were made available following request to the original authors.
- 771

772 8. Conflicts of Interest

773 CML is on the Scientific Advisory Board of Myriad Neuroscience and has received774 honoraria for consultancy from UCB. C.L.-Q. has received consultancy fees from

775 Pfizer. C.L.-Q. has received honoraria, travel or speakers' fees from Biogen and

research funds from Pfizer and Novo Nordisk. C.L.-Q. is the director of the company

777 BrainLogia. All other authors declare no competing interests.

778 References

- Plana-Ripoll, O. *et al.* Exploring comorbidity within mental disorders among a danish national population. *JAMA Psychiatry* 76, 259–270 (2019).
- Grotzinger, A. D. *et al.* Genetic architecture of 11 major psychiatric disorders at
 biobehavioral, functional genomic and molecular genetic levels of analysis. *Nat. Genet.* 54, 548–559 (2022).
- Aarsland, D. *et al.* Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. *J. Neurol. Neurosurg. Psychiatry* 78, 36–42 (2007).
- Turner, M. R., Goldacre, R., Talbot, K. & Goldacre, M. J. Psychiatric disorders prior to amyotrophic lateral sclerosis. *Ann. Neurol.* 80, 935–938 (2016).
- 5. Ismail, Z. *et al.* Psychosis in Alzheimer disease mechanisms, genetics and therapeutic opportunities. *Nat. Rev. Neurol.* 18, 131–144 (2022).
- 6. Chertcoff, A. S. *et al.* Psychiatric comorbidity during the prodromal period in patients with multiple sclerosis. *Neurology* 101, e2026–e2034 (2023).
- 794 7. Burchill, E. *et al.* The impact of psychiatric comorbidity on Parkinson's disease
 795 outcomes: a systematic review and meta-analysis. *Lancet Reg. Health Eur.* 39, 100870
 796 (2024).
- 8. Wainberg, M., Andrews, S. J. & Tripathy, S. J. Shared genetic risk loci between
 Alzheimer's disease and related dementias, Parkinson's disease, and amyotrophic
 lateral sclerosis. *Alzheimers Res. Ther.* 15, 113 (2023).
- Wightman, D. P. *et al.* The genetic overlap between Alzheimer's disease, amyotrophic
 lateral sclerosis, Lewy body dementia, and Parkinson's disease. *Neurobiol. Aging* 127,
 99–112 (2023).
- 803 10. Gimson, A., Schlosser, M., Huntley, J. D. & Marchant, N. L. Support for midlife
 804 anxiety diagnosis as an independent risk factor for dementia: a systematic review. *BMJ*805 *Open* 8, e019399 (2018).
- Kuusimäki, T. *et al.* Increased risk of parkinson's disease in patients with schizophrenia
 spectrum disorders. *Mov. Disord.* 36, 1353–1361 (2021).
- Richmond-Rakerd, L. S., D'Souza, S., Milne, B. J., Caspi, A. & Moffitt, T. E.
 Longitudinal Associations of Mental Disorders With Dementia: 30-Year Analysis of
 1.7 Million New Zealand Citizens. *JAMA Psychiatry* 79, 333–340 (2022).
- 811 13. Andreassen, O. A. *et al.* Genetic pleiotropy between multiple sclerosis and
 812 schizophrenia but not bipolar disorder: differential involvement of immune-related gene
 813 loci. *Mol. Psychiatry* 20, 207–214 (2015).
- 814 14. McLaughlin, R. L. *et al.* Genetic correlation between amyotrophic lateral sclerosis and
 815 schizophrenia. *Nat. Commun.* 8, 14774 (2017).
- 816 15. Reynolds, R. H. *et al.* Local genetic correlations exist among neurodegenerative and
 817 neuropsychiatric diseases. *npj Parkinsons Disease* 9, 70 (2023).
- 818 16. Wingo, T. S. *et al.* Shared mechanisms across the major psychiatric and neurodegenerative diseases. *Nat. Commun.* 13, 4314 (2022).
- Harerimana, N. V. *et al.* Genetic evidence supporting a causal role of depression in alzheimer's disease. *Biol. Psychiatry* 92, 25–33 (2022).
- Patti, G. J., Yanes, O. & Siuzdak, G. Innovation: Metabolomics: the apogee of the omics trilogy. *Nat. Rev. Mol. Cell Biol.* 13, 263–269 (2012).
- B24 19. Guijas, C., Montenegro-Burke, J. R., Warth, B., Spilker, M. E. & Siuzdak, G.
 Metabolomics activity screening for identifying metabolites that modulate phenotype.
 Nat. Biotechnol. 36, 316–320 (2018).

- 827 20. Garana, B. B. & Graham, N. A. Metabolomics paves the way for improved drug target identification. *Mol. Syst. Biol.* 18, e10914 (2022).
- Rinschen, M. M., Ivanisevic, J., Giera, M. & Siuzdak, G. Identification of bioactive
 metabolites using activity metabolomics. *Nat. Rev. Mol. Cell Biol.* 20, 353–367 (2019).
- 831 22. Gowda, G. A. N. *et al.* Metabolomics-based methods for early disease diagnostics.
 832 *Expert Rev Mol Diagn* 8, 617–633 (2008).
- Binoff, A., Herrmann, N. & Lanctôt, K. L. Ceramides and depression: A systematic review. J. Affect. Disord. 213, 35–43 (2017).
- Brunkhorst-Kanaan, N. *et al.* Targeted lipidomics reveal derangement of ceramides in major depression and bipolar disorder. *Metab. Clin. Exp.* 95, 65–76 (2019).
- 837 25. Filippatou, A. G. *et al.* Serum ceramide levels are altered in multiple sclerosis. *Mult.*838 *Scler.* 27, 1506–1519 (2021).
- Chowdhury, M. R., Jin, H. K. & Bae, J.-S. Diverse roles of ceramide in the progression
 and pathogenesis of alzheimer's disease. *Biomedicines* 10, (2022).
- 841 27. Vos, M., Klein, C. & Hicks, A. A. Role of ceramides and sphingolipids in parkinson's
 842 disease. *J. Mol. Biol.* 435, 168000 (2023).
- 28. Davey Smith, G. & Ebrahim, S. Epidemiology--is it time to call it a day? *Int. J. Epidemiol.* 30, 1–11 (2001).
- 845 29. Webhofer, C. *et al.* Metabolite profiling of antidepressant drug action reveals novel drug targets beyond monoamine elevation. *Transl. Psychiatry* 1, e58 (2011).
- 847 30. Pillinger, T. *et al.* Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. *Lancet Psychiatry* 7, 64–77 (2020).
- Shao, Y. *et al.* Comprehensive metabolic profiling of Parkinson's disease by liquid
 chromatography-mass spectrometry. *Mol. Neurodegener.* 16, 4 (2021).
- 853 32. Pu, J. *et al.* Effects of pharmacological treatment on metabolomic alterations in animal
 854 models of depression. *Transl. Psychiatry* 12, 175 (2022).
- 33. Murgia, F. *et al.* Metabolomic Changes in Patients Affected by Multiple Sclerosis and
 Treated with Fingolimod. *Metabolites* 13, (2023).
- 857 34. Lawlor, D. A., Harbord, R. M., Sterne, J. A. C., Timpson, N. & Davey Smith, G.
 858 Mendelian randomization: using genes as instruments for making causal inferences in
 859 epidemiology. *Stat. Med.* 27, 1133–1163 (2008).
- Smith, G. D. & Ebrahim, S. "Mendelian randomization": can genetic epidemiology
 contribute to understanding environmental determinants of disease? *Int. J. Epidemiol.*32, 1–22 (2003).
- 36. Abdellaoui, A., Yengo, L., Verweij, K. J. H. & Visscher, P. M. 15 years of GWAS
 discovery: Realizing the promise. *Am. J. Hum. Genet.* 110, 179–194 (2023).
- 37. Lord, J. *et al.* Disentangling independent and mediated causal relationships between
 blood metabolites, cognitive factors, and alzheimer's disease. *Biological Psychiatry Global Open Science* 2, 167–179 (2022).
- 38. Zacharias, H. U. *et al.* A metabolome-wide association study in the general population reveals decreased levels of serum laurylcarnitine in people with depression. *Mol.*870 *Psychiatry* 26, 7372–7383 (2021).
- Bavyson, E. *et al.* Metabolomic investigation of major depressive disorder identifies a potentially causal association with polyunsaturated fatty acids. *Biol. Psychiatry* 94, 630–639 (2023).
- 40. Ge, A., Sun, Y., Kiker, T., Zhou, Y. & Ye, K. A metabolome-wide Mendelian
 randomization study prioritizes potential causal circulating metabolites for multiple
 sclerosis. J. Neuroimmunol. 379, 578105 (2023).

- 877 41. Stacey, D., Benyamin, B., Lee, S. H. & Hyppönen, E. A Metabolome-Wide Mendelian
 878 Randomization Study Identifies Dysregulated Arachidonic Acid Synthesis as a
 879 Potential Causal Risk Factor for Bipolar Disorder. *Biol. Psychiatry* (2024).
 880 doi:10.1016/j.biopsych.2024.02.1005
- 42. Purves, K. L. *et al.* A major role for common genetic variation in anxiety disorders. *Mol. Psychiatry* 25, 3292–3303 (2020).
- 43. Meier, S. M. *et al.* Genetic Variants Associated With Anxiety and Stress-Related
 Disorders: A Genome-Wide Association Study and Mouse-Model Study. *JAMA Psychiatry* (2019). doi:10.1001/jamapsychiatry.2019.1119
- Kurki, M. I. *et al.* FinnGen provides genetic insights from a well-phenotyped isolated
 population. *Nature* 613, 508–518 (2023).
- Mullins, N. *et al.* Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. *Nat. Genet.* 53, 817–829
 (2021).
- 46. Howard, D. M. *et al.* Genome-wide meta-analysis of depression identifies 102
 independent variants and highlights the importance of the prefrontal brain regions. *Nat. Neurosci.* 22, 343–352 (2019).
- 47. Levey, D. F. *et al.* Bi-ancestral depression GWAS in the Million Veteran Program and
 meta-analysis in >1.2 million individuals highlight new therapeutic directions. *Nat. Neurosci.* 24, 954–963 (2021).
- 48. Trubetskoy, V. *et al.* Mapping genomic loci implicates genes and synaptic biology in schizophrenia. *Nature* 604, 502–508 (2022).
- 49. van Rheenen, W. *et al.* Common and rare variant association analyses in amyotrophic
 lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuronspecific biology. *Nat. Genet.* 53, 1636–1648 (2021).
- 902 50. International Multiple Sclerosis Genetics Consortium. Multiple sclerosis genomic map
 903 implicates peripheral immune cells and microglia in susceptibility. *Science* 365, (2019).
- 904 51. Nalls, M. A. *et al.* Identification of novel risk loci, causal insights, and heritable risk for
 905 Parkinson's disease: a meta-analysis of genome-wide association studies. *Lancet*906 *Neurol.* 18, 1091–1102 (2019).
- 907 52. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* 26, 2190–2191 (2010).
- 53. Liu, H. *et al.* Mendelian randomization highlights significant difference and genetic
 heterogeneity in clinically diagnosed Alzheimer's disease GWAS and self-report proxy
 phenotype GWAX. *Alzheimers Res. Ther.* 14, 17 (2022).
- 54. Lumsden, A. L., Mulugeta, A., Zhou, A. & Hyppönen, E. Apolipoprotein E (APOE)
 genotype-associated disease risks: a phenome-wide, registry-based, case-control study
 utilising the UK Biobank. *EBioMedicine* 59, 102954 (2020).
- 915 55. Bulik-Sullivan, B. *et al.* LD Score regression distinguishes confounding from
 916 polygenicity in genome-wide association studies. *Nat. Genet.* 47, 291–295 (2015).
- 56. Grotzinger, A. D. *et al.* Genomic structural equation modelling provides insights into
 the multivariate genetic architecture of complex traits. *Nat. Hum. Behav.* 3, 513–525
 (2019).
- 920 57. Grotzinger, A. D., Fuente, J. de la, Privé, F., Nivard, M. G. & Tucker-Drob, E. M.
 921 Pervasive Downward Bias in Estimates of Liability-Scale Heritability in Genome-wide
 922 Association Study Meta-analysis: A Simple Solution. *Biol. Psychiatry* 93, 29–36
 923 (2023).
- 58. Chen, Y. *et al.* Genomic atlas of the plasma metabolome prioritizes metabolites
 implicated in human diseases. *Nat. Genet.* 55, 44–53 (2023).
- 926 59. Hysi, P. G. et al. Metabolome Genome-Wide Association Study Identifies 74 Novel

927 Genomic Regions Influencing Plasma Metabolites Levels. *Metabolites* 12, (2022). Murphy, A. E., Schilder, B. M. & Skene, N. G. MungeSumstats: A Bioconductor 928 60. package for the standardisation and quality control of many GWAS summary statistics. 929 930 Bioinformatics (2021). doi:10.1093/bioinformatics/btab665 Chang, C. C. et al. Second-generation PLINK: rising to the challenge of larger and 931 61. richer datasets. Gigascience 4, s13742-015-0047-8 (2015). 932 933 62. 1000 Genomes Project Consortium et al. A global reference for human genetic 934 variation. Nature 526, 68-74 (2015). Elsworth, B. et al. The MRC IEU OpenGWAS data infrastructure. BioRxiv (2020). 935 63. 936 doi:10.1101/2020.08.10.244293 64. Palmos, A. B. et al. Proteome-wide Mendelian randomization identifies causal links 937 938 between blood proteins and severe COVID-19. PLoS Genet. 18, e1010042 (2022). Bowden, J. et al. Assessing the suitability of summary data for two-sample Mendelian 939 65. 940 randomization analyses using MR-Egger regression: the role of the I2 statistic. Int. J. 941 *Epidemiol.* **45,** 1961–1974 (2016). 66. Burgess, S. et al. Guidelines for performing Mendelian randomization investigations: 942 update for summer 2023. Wellcome Open Res. 4, 186 (2019). 943 Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and 944 67. powerful approach to multiple testing. Journal of the Royal Statistical Society: Series B 945 946 (Methodological) 57, 289–300 (1995). 947 68. Bowden, J., Davey Smith, G., Haycock, P. C. & Burgess, S. Consistent Estimation in 948 Mendelian Randomization with Some Invalid Instruments Using a Weighted Median 949 Estimator. Genet. Epidemiol. 40, 304–314 (2016). 950 69. Burgess, S., Bowden, J., Dudbridge, F. & Thompson, S. G. Robust instrumental variable methods using multiple candidate instruments with application to Mendelian 951 952 randomization. arXiv (2016). doi:10.48550/arxiv.1606.03729 Xue, H., Shen, X. & Pan, W. Constrained maximum likelihood-based Mendelian 953 70. 954 randomization robust to both correlated and uncorrelated pleiotropic effects. Am. J. 955 Hum. Genet. 108, 1251–1269 (2021). Burgess, S., Foley, C. N., Allara, E., Staley, J. R. & Howson, J. M. M. A robust and 956 71. efficient method for Mendelian randomization with hundreds of genetic variants. Nat. 957 Commun. 11, 376 (2020). 958 72. Rees, J. M. B., Wood, A. M., Dudbridge, F. & Burgess, S. Robust methods in 959 Mendelian randomization via penalization of heterogeneous causal estimates. PLoS 960 One 14, e0222362 (2019). 961 Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid 962 73. 963 instruments: effect estimation and bias detection through Egger regression. Int. J. Epidemiol. 44, 512–525 (2015). 964 965 74. Zhu, Z. et al. Causal associations between risk factors and common diseases inferred 966 from GWAS summary data. Nat. Commun. 9, 224 (2018). Yengo, L. et al. Meta-analysis of genome-wide association studies for height and body 967 75. 968 mass index in ~700000 individuals of European ancestry. Hum. Mol. Genet. 27, 3641-3649 (2018). 969 Pulit, S. L. et al. Meta-analysis of genome-wide association studies for body fat 970 76. 971 distribution in 694 649 individuals of European ancestry. Hum. Mol. Genet. 28, 166-972 174 (2019). Okbay, A. et al. Polygenic prediction of educational attainment within and between 973 77. 974 families from genome-wide association analyses in 3 million individuals. Nat. Genet. 975 **54,** 437–449 (2022). Zuber, V., Colijn, J. M., Klaver, C. & Burgess, S. Selecting likely causal risk factors 976 78.

- 977 from high-throughput experiments using multivariable Mendelian randomization. *Nat.*978 *Commun.* 11, 29 (2020).
- 979 79. Lord, J. *et al.* Mendelian randomization identifies blood metabolites previously linked
 980 to midlife cognition as causal candidates in Alzheimer's disease. *Proc. Natl. Acad. Sci.*981 USA 118, (2021).
- 80. Vilhjálmsson, B. J. *et al.* Modeling linkage disequilibrium increases accuracy of
 polygenic risk scores. *Am. J. Hum. Genet.* 97, 576–592 (2015).
- 81. Choi, S. W., Mak, T. S.-H. & O'Reilly, P. F. Tutorial: a guide to performing polygenic risk score analyses. *Nat. Protoc.* 15, 2759–2772 (2020).
- 986 82. Pain, O., Al-Chalabi, A. & Lewis, C. M. The genopred pipeline: A comprehensive and
 987 scalable pipeline for polygenic scoring. *medRxiv* (2024).
 988 doi:10.1101/2024.06.12.24308843
- 83. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature* 562, 203–209 (2018).
- 84. Zhang, Q., Privé, F., Vilhjálmsson, B. & Speed, D. Improved genetic prediction of
 complex traits from individual-level data or summary statistics. *Nat. Commun.* 12, 4192
 (2021).
- 85. Ni, G. *et al.* A comparison of ten polygenic score methods for psychiatric disorders
 applied across multiple cohorts. *Biol. Psychiatry* 90, 611–620 (2021).
- 86. Monti, R. *et al.* Evaluation of polygenic scoring methods in five biobanks shows larger variation between biobanks than methods and finds benefits of ensemble learning. *Am. J. Hum. Genet.* 111, 1431–1447 (2024).
- 87. Manichaikul, A. *et al.* Robust relationship inference in genome-wide association
 studies. *Bioinformatics* 26, 2867–2873 (2010).
- 1001 88. Spargo, T. P. *et al.* Statistical examination of shared loci in neuropsychiatric diseases
 1002 using genome-wide association study summary statistics. (2023).
 1003 doi:10.7554/eLife.88768
- 1004 89. Giambartolomei, C. *et al.* Bayesian test for colocalisation between pairs of genetic
 1005 association studies using summary statistics. *PLoS Genet.* 10, e1004383 (2014).
- 90. Võsa, U. *et al.* Large-scale cis- and trans-eQTL analyses identify thousands of genetic
 loci and polygenic scores that regulate blood gene expression. *Nat. Genet.* 53, 1300–
 1310 (2021).
- 1009 91. Zhu, Z. *et al.* Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. *Nat. Genet.* 48, 481–487 (2016).
- 1011 92. Westra, H.-J. *et al.* Systematic identification of trans eQTLs as putative drivers of known disease associations. *Nat. Genet.* 45, 1238–1243 (2013).
- 1013 93. Lloyd-Jones, L. R. *et al.* The genetic architecture of gene expression in peripheral
 1014 blood. *Am. J. Hum. Genet.* 100, 228–237 (2017).
- 1015 94. Auwerx, C. *et al.* Exploiting the mediating role of the metabolome to unravel transcript1016 to-phenotype associations. *Elife* 12, (2023).
- 1017 95. Yoshiji, S. *et al.* Proteome-wide Mendelian randomization implicates nephronectin as an actionable mediator of the effect of obesity on COVID-19 severity. *Nat. Metab.* 5, 248–264 (2023).
- 1020 96. Koletzko, B. *et al.* FADS1 and FADS2 polymorphisms modulate fatty acid metabolism
 1021 and dietary impact on health. *Annu. Rev. Nutr.* 39, 21–44 (2019).
- 97. Myers, T. A., Chanock, S. J. & Machiela, M. J. Ldlinkr: an R package for rapidly
 calculating linkage disequilibrium statistics in diverse populations. *Front. Genet.* 11,
 157 (2020).
- 1025 98. Jansen, R. *et al.* The Metabolome-Wide Signature of Major Depressive Disorder. *Res.*1026 Sq. (2023). doi:10.21203/rs.3.rs-3127544/v1

- 1027 99. Zeng, L. *et al.* Causal effects of fatty acids on depression: Mendelian randomization study. *Front. Nutr.* 9, 1010476 (2022).
- 1029 100. Gao, Y. *et al.* Association between Arachidonic Acid and the Risk of Schizophrenia: A
 1030 Cross-National Study and Mendelian Randomization Analysis. *Nutrients* 15, (2023).
- 1031 101. Whelan, J. & Fritsche, K. Linoleic acid. *Adv. Nutr.* 4, 311–312 (2013).
- 1032 102. Tallima, H. & El Ridi, R. Arachidonic acid: Physiological roles and potential health
 1033 benefits A review. *J. Advanc. Res.* 11, 33–41 (2018).
- 1034 103. Innes, J. K. & Calder, P. C. Omega-6 fatty acids and inflammation. *Prostaglandins* 1035 *Leukot Essent Fatty Acids* 132, 41–48 (2018).
- 1036 104. Yuan, N., Chen, Y., Xia, Y., Dai, J. & Liu, C. Inflammation-related biomarkers in major psychiatric disorders: a cross-disorder assessment of reproducibility and specificity in 43 meta-analyses. *Transl. Psychiatry* 9, 233 (2019).
- 1039 105. Perry, B. I. *et al.* Associations of immunological proteins/traits with schizophrenia, major depression and bipolar disorder: A bi-directional two-sample mendelian
 1041 randomization study. *Brain Behav. Immun.* 97, 176–185 (2021).
- 1042 106. Wang, L., Luo, G., Zhang, L.-F. & Geng, H.-X. Neuroprotective effects of
 1043 epoxyeicosatrienoic acids. *Prostaglandins Other Lipid Mediat* 138, 9–14 (2018).
- 1044 107. Su, K.-P. *et al.* Phospholipase A2 and cyclooxygenase 2 genes influence the risk of
 1045 interferon-alpha-induced depression by regulating polyunsaturated fatty acids levels.
 1046 *Biol. Psychiatry* 67, 550–557 (2010).
- 1047 108. Adams, C. D. Circulating glutamine and alzheimer's disease: A mendelian
 1048 randomization study. *Clin Interv Aging* 15, 185–193 (2020).
- 1049 109. Chen, J. & Herrup, K. Glutamine acts as a neuroprotectant against DNA damage, beta1050 amyloid and H2O2-induced stress. *PLoS One* 7, e33177 (2012).
- 1051 110. Sims, J. R. *et al.* Donanemab in Early Symptomatic Alzheimer Disease: The
 1052 TRAILBLAZER-ALZ 2 Randomized Clinical Trial. *JAMA* 330, 512–527 (2023).
- 1053 111. Bernal-Vega, S., García-Juárez, M. & Camacho-Morales, A. Contribution of ceramides 1054 metabolism in psychiatric disorders. *J. Neurochem.* 164, 708–724 (2023).
- 1055 112. Zhuo, C. *et al.* Acid sphingomyelinase/ceramide system in schizophrenia: implications
 1056 for therapeutic intervention as a potential novel target. *Transl. Psychiatry* 12, 260
 1057 (2022).
- 1058 113. Pekala, J. *et al.* L-carnitine--metabolic functions and meaning in humans life. *Curr* 1059 Drug Metab 12, 667–678 (2011).
- 1060 114. Beghi, E. *et al.* Randomized double-blind placebo-controlled trial of acetyl-L-carnitine
 1061 for ALS. *Amyotroph. Lateral Scler. Frontotemporal Degener.* 14, 397–405 (2013).
- 1062 115. Pennisi, M. *et al.* Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A
 1063 Critical Update. *Nutrients* 12, (2020).
- 1064 116. Gharighnia, S., Omidi, A., Ragerdi Kashani, I., Sepand, M. R. & Pour Beiranvand, S.
 1065 Ameliorative effects of acetyl-L-carnitine on corpus callosum and functional recovery
 1066 in demyelinated mouse model. *Int. J. Neurosci.* 1–11 (2022).
 1067 doi:10.1080/00207454.2022.2107515
- 1068 117. Sarraf, P. *et al.* The correlation of the serum level of L-carnitine with disease severity in patients with Amyotrophic lateral sclerosis. *J. Clin. Neurosci.* 89, 232–236 (2021).
- 1070 118. Harirchian, M. H., Babaie, S., Keshtkaran, N. & Bitarafan, S. The association of serum carnitine levels with severity of fatigue in patients with multiple sclerosis: A pilot study. *CJN* 22, 30–34 (2023).
- 1073 119. Custers, Emma, E. M., Kiliaan & Amanda, J. Dietary lipids from body to brain. *Prog. Lipid Res.* 85, 101144 (2022).
- 1075 120. Zahoor, I., Rui, B., Khan, J., Datta, I. & Giri, S. An emerging potential of metabolomics
 1076 in multiple sclerosis: a comprehensive overview. *Cell Mol. Life Sci.* 78, 3181–3203

1077 (2021).

- 1078 121. Zhang, Y., Guo, S., Xie, C. & Fang, J. Uridine metabolism and its role in glucose, lipid, and amino acid homeostasis. *Biomed Res. Int.* 2020, 7091718 (2020).
- 1080 122. Zhang, Y. *et al.* Plasma branched-chain and aromatic amino acids correlate with the gut
 1081 microbiota and severity of Parkinson's disease. *npj Parkinsons Disease* 8, 48 (2022).
- 1082 123. Barichella, M. *et al.* Muscle-targeted nutritional support for rehabilitation in patients
 1083 with parkinsonian syndrome. *Neurology* 93, e485–e496 (2019).
- 1084 124. Lewis, C. M. & Vassos, E. Polygenic risk scores: from research tools to clinical
 1085 instruments. *Genome Med.* 12, 44 (2020).
- 1086 125. Albiñana, C. *et al.* Multi-PGS enhances polygenic prediction by combining 937
 1087 polygenic scores. *Nat. Commun.* 14, 4702 (2023).
- 1088 126. Yang, L. G., March, Z. M., Stephenson, R. A. & Narayan, P. S. Apolipoprotein E in
 1089 lipid metabolism and neurodegenerative disease. *Trends Endocrinol. Metab.* 34, 430–
 1090 445 (2023).